ZSCAN12 and cancer: The WID-qEC test, based on ZSCAN12 and GYPC DNA methylation, appeared to be an excellent predictor of near-term (<1 year) EC risk (sensitivity: 91%; specificity: 100%), but not effective in assessing long-term (≥ 1 year) cancer risk (sensitivity: 20%) (60).